Medications for weight loss
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Overweight and obesity together with their comorbidities have become increasingly prevalent worldwide. The need for well tolerated, effective interventions has become increasingly urgent. Here we review the pharmacology, benefits, and risks of Western and Chinese medications used for weight loss. RECENT FINDINGS: Lifestyle interventions for weight loss are efficacious, but have had limited long-term durability. Bariatric surgery is very effective for weight loss and reversal of type 2 diabetes mellitus (T2DM), but it is invasive and not consistently durable in all patients. Recent studies show that newer Western pharmaceuticals and some traditional Chinese medications may be effective for appropriate patients in need of weight loss. SUMMARY: New Western medications, notably lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide, are more effective and possibly safer than older medications but have important side-effects. Chinese herbal medicines may have efficacy similar to that of older Western medications and with few side-effects, but data are limited. We suggest that for appropriate patients, in particular those with or at high risk for T2DM, the judicious use of these medications with lifestyle modification is justified. This may be particularly true in Asia where T2DM develops at a low BMI, though more data are needed to support this concept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“In addition, studies to determine whether modest weight loss achieved with these medications can, as in Western patients [5], prevent the progress of impaired glucose tolerance to diabetes to a significant extent remain to be performed.”
BackgroundDiabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 3×
“In particular, patients at risk for T2DM can benefit from 5 to 10-kg weight loss, as documented in the DPP [6] and other trials [51].”
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · cited 1×
“Success rates for weight loss, reversal of T2DM, and reduction in mortality are high [14,15].”
BackgroundComparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 1×
“In general, programs focused on dieting have had limited success over periods of more than 2 years irrespective of nutritional content [9,10], and only a minority of adult Americans [11] or Chinese [12 & ] engage in regular exercise.”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“Additional diabetes medications that are associated with weight loss are pramlintide and other GLP-1 agonists including exenatide [40], dulaglutide, and albiglutide [41].”
BackgroundGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Gardner, C. D., Kiazand, A., Alhassan, S., Kim, S., Stafford, R. S., Balise, R. R., Kraemer, H. C., & King, A. C. (2007) · JAMA · doi:10.1001/jama.297.9.969 · Cited by 1,051
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Cited by
Weight gain and metabolic changes during treatment with antipsychotics and antidepressants
Himmerich, H., Minkwitz, J., & Kirkby, K. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150623092031 · Cited by 122
Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112
GLP-1 Influences Food and Drug Reward
Hayes, M. R., & Schmidt, H. D. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.02.005 · Cited by 108
Vosburg, R. W., El Chaar, M., El Djouzi, S., Docimo, S., Choi, D., LaMasters, T., Srivastava, G., Shukla, A. P., Oviedo, R. J., Fitch, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.07.002 · Cited by 24
Metadata
- Authors
- Mordes, J. P., Liu, C., & Xu, S.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2015-04
- Volume
- 22
- Issue
- 2
- Pages
- 91-97
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W2105792488
- Cited by
- 30
- References
- 24
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medications for weight loss. https://app.cochat.ai/papers/10.1097/med.0000000000000140
- The paper
- Mordes, J. P., Liu, C., & Xu, S. (2015). Medications for weight loss. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.